Literature DB >> 6783652

Large scale isolation of functionally active components of the human complement system.

C H Hammer, G H Wirtz, L Renfer, H D Gresham, B F Tack.   

Abstract

In the present work a scheme is presented for the isolation of multiple components of human complement in a functionally and biochemically pure state and with full hemolytic activity. These preparative procedures allow high recovery of milligram and gram quantities of particular complement components from a large pool (2-11 liters) of fresh EDTA plasma in no more than four chromatographic steps. Many components (C3bINA, C5, C3, C1EI, C4, and C9) are recovered functionally pure or highly purified following the first chromatographic step employing DEAE-Sephacel and may be utilized as reagents with no further purification. Prior to anion exchange, individual units of plasma are treated with inhibitors of complement activation and serum proteases, the pooled plasma is fractionated with polyethylene glycol, depleted of plasminogen on Sepharose-lysine, and rapidly ultrafiltered to low ionic strength and high protein concentration. The high degree of resolution of the components on DEAE-Sephacel subsequently obtained is demonstrated by the functional recovery and purification in a representative experiment as indicated (in their order of elution) for the following proteins: C3bINA (24%, 18-fold), C2 (74%, 12-fold), C7 (87%, 14-fold), factor B (55%, 8.7-fold),, C8 (50%, 16-fold), C6 (82%, 25-fold), beta 1H (39%, 12-fold), C5 (62%, 111-fold), C3 (99%, 64-fold), C1EI (42%, 135-fold), C9 (80%, 297-fold), and c4 (78%, 164-fold). Other components separated by these procedures include C1q and C4 binding protein. Additional steps described, which demonstrate the utility and effectiveness of this preparative scheme, have allowed isolation of C3, C5, and C7 as pure components with full hemolytic activity as judged by functional, immunochemical, and physicochemical criteria. C8, also isolated as a homogeneous protein, was recovered with partial hemolytic activity. All these components were recovered in high yield and in the purification as indicated: C3 (61%, 103-fold), C5 (24% 1350-fold), C7 (19%, 2260-fold), and C8 (32%, 547-fold). Complement components C6, beta 1H, factor B, and C2 in addition to C3bINA, C1EI, C4, and C9 are recovered partially purified with good activity and are amenable to further purification.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6783652

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  138 in total

1.  Involvement of the ERK mitogen-activated protein kinase in cell resistance to complement-mediated lysis.

Authors:  S Kraus; R Seger; Z Fishelson
Journal:  Clin Exp Immunol       Date:  2001-03       Impact factor: 4.330

2.  Serum amyloid P component bound to gram-negative bacteria prevents lipopolysaccharide-mediated classical pathway complement activation.

Authors:  C J de Haas; E M van Leeuwen; T van Bommel; J Verhoef; K P van Kessel; J A van Strijp
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

3.  Interaction of C3b(2)--IgG complexes with complement proteins properdin, factor B and factor H: implications for amplification.

Authors:  E Jelezarova; A Vogt; H U Lutz
Journal:  Biochem J       Date:  2000-07-01       Impact factor: 3.857

4.  Native polymeric forms of properdin selectively bind to targets and promote activation of the alternative pathway of complement.

Authors:  Viviana P Ferreira; Claudio Cortes; Michael K Pangburn
Journal:  Immunobiology       Date:  2010-02-12       Impact factor: 3.144

5.  Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins.

Authors:  T R Kozel; M A Wilson; G S Pfrommer; A M Schlageter
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

6.  Pathogenesis of Campylobacter fetus infections. Failure of encapsulated Campylobacter fetus to bind C3b explains serum and phagocytosis resistance.

Authors:  M J Blaser; P F Smith; J E Repine; K A Joiner
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

7.  Multimeric complement component C9 is necessary for killing of Escherichia coli J5 by terminal attack complex C5b-9.

Authors:  K A Joiner; M A Schmetz; M E Sanders; T G Murray; C H Hammer; R Dourmashkin; M M Frank
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

8.  Sequence determination of the thiolester site of the fourth component of human complement.

Authors:  R A Harrison; M L Thomas; B F Tack
Journal:  Proc Natl Acad Sci U S A       Date:  1981-12       Impact factor: 11.205

9.  Polymerization of the ninth component of complement (C9): formation of poly(C9) with a tubular ultrastructure resembling the membrane attack complex of complement.

Authors:  E R Podack; J Tschopp
Journal:  Proc Natl Acad Sci U S A       Date:  1982-01       Impact factor: 11.205

10.  Dynamic structural changes during complement C3 activation analyzed by hydrogen/deuterium exchange mass spectrometry.

Authors:  Michael C Schuster; Daniel Ricklin; Krisztián Papp; Kathleen S Molnar; Stephen J Coales; Yoshitomo Hamuro; Georgia Sfyroera; Hui Chen; Michael S Winters; John D Lambris
Journal:  Mol Immunol       Date:  2008-05-05       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.